Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ASND 
Ascendis Pharma AS (ASND)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ASND (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $251.6
1 Year Target Price $251.6
| 12 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.61% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.74B USD | Price to earnings Ratio - | 1Y Target Price 251.6 |
Price to earnings Ratio - | 1Y Target Price 251.6 | ||
Volume (30-day avg) 16 | Beta 0.4 | 52 Weeks Range 111.09 - 199.99 | Updated Date 08/29/2025 |
52 Weeks Range 111.09 - 199.99 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -1.27 | Actual -0.82 |
Profitability
Profit Margin -55.25% | Operating Margin (TTM) -33.5% |
Management Effectiveness
Return on Assets (TTM) -17.17% | Return on Equity (TTM) -818.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12087497488 | Price to Sales(TTM) 23.93 |
Enterprise Value 12087497488 | Price to Sales(TTM) 23.93 | ||
Enterprise Value to Revenue 21.15 | Enterprise Value to EBITDA -20.75 | Shares Outstanding 60554400 | Shares Floating 60083295 |
Shares Outstanding 60554400 | Shares Floating 60083295 | ||
Percent Insiders 0.78 | Percent Institutions 109.36 |
Upturn AI SWOT
Ascendis Pharma AS
Company Overview
History and Background
Ascendis Pharma AS is a biopharmaceutical company founded in 2006, headquartered in Hellerup, Denmark. It focuses on developing therapies for unmet medical needs using its TransCon technology platform. Key milestones include FDA approval of Skytrofa for pediatric growth hormone deficiency in 2021 and ongoing clinical trials for other endocrinology and oncology indications.
Core Business Areas
- Endocrinology: Develops and commercializes therapies for endocrine disorders, primarily focused on growth hormone deficiency and hypoparathyroidism.
- Oncology: Develops therapies for oncology, leveraging the TransCon technology to create targeted cancer treatments.
Leadership and Structure
The company is led by Jan Mikkelsen (President and CEO). It operates with a functional organizational structure, with departments focused on research and development, clinical trials, commercialization, and corporate operations.
Top Products and Market Share
Key Offerings
- Skytrofa (lonapegsomatropin-tcgd): A long-acting growth hormone approved for pediatric growth hormone deficiency. Expected peak sales are significant. Competitors include Pfizer's Genotropin, Novo Nordisk's Norditropin and Merck's Saizen. Estimated market share as a relatively new entrant is still evolving but with potential to grow considerably.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, strict regulatory requirements, and significant competition. The market for growth hormone therapies is well-established but has room for innovation with longer-acting formulations.
Positioning
Ascendis Pharma AS is positioned as an innovative player in the endocrinology space, focusing on developing differentiated therapies using its TransCon technology. The company's long-acting growth hormone has provided them a competitive advantage.
Total Addressable Market (TAM)
The TAM for growth hormone deficiency and related endocrine disorders is in the billions of dollars. Ascendis Pharma AS is targeting a significant portion of this TAM with Skytrofa and other pipeline products.
Upturn SWOT Analysis
Strengths
- TransCon technology platform
- FDA-approved product (Skytrofa)
- Strong pipeline of product candidates
- Experienced management team
- Strong Intellectual Property portfolio
Weaknesses
- High operating expenses
- Reliance on successful clinical trial outcomes
- Competition from established pharmaceutical companies
- Dependence on single product for revenue
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Acquisition of complementary technologies
- Geographic expansion into new markets
Threats
- Failure of clinical trials
- Regulatory hurdles
- Patent expiration
- Competition from biosimilars
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- PFE
- NVO
- MRK
Competitive Landscape
Ascendis Pharma AS has a competitive advantage with its long-acting growth hormone. It faces challenges from established players with broader portfolios and larger commercial operations.
Growth Trajectory and Initiatives
Historical Growth: Ascendis Pharma AS has experienced rapid growth in revenue with the launch of Skytrofa. Historical net losses reflect the cost of R&D and commercialization.
Future Projections: Analysts project continued revenue growth driven by Skytrofa and pipeline advancements. Profitability is expected to improve as revenue scales.
Recent Initiatives: Recent initiatives include expanding the Skytrofa label, advancing clinical trials for other pipeline products, and building commercial infrastructure.
Summary
Ascendis Pharma AS is a growing biopharmaceutical company with a novel technology platform. The approval and launch of Skytrofa is a significant achievement, but the company still faces challenges in terms of profitability and competition. The success of its pipeline products will be crucial for its long-term growth. However, the company shows a strong trend and potential to be profitable in the near future with Skytrofa.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly. Data is based on publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ascendis Pharma AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-01-28 | President, CEO, Member of Executive Board & Executive Director Mr. Jan Moller Mikkelsen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1017 | Website https://ascendispharma.com |
Full time employees 1017 | Website https://ascendispharma.com | ||
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.